Zoek in het archief
 
terug

Check the original
News breaking: 2017-07-10

Nieuwe therapie voor auto-immuunziekte biedt miljoenen pati√ęnten in meer dan honderd landen hoop

08:30 uur 09-07-2017

Nieuwe therapie voor auto-immuunziekte biedt miljoenen pati√ęnten in meer dan honderd landen hoop

RIYAD, Saudi-Arabi√ę‚Äď(BUSINESS WIRE)‚Äď Hoogleraar Tadamitsu Kishimoto van de Universiteit van Osaka, winnaar van de King Faisal International Prize for Medicine 2017, heeft gezegd dat meer dan honderd landen, met inbegrip van Saudi-Arabi√ę, een effectieve biologische methode hebben ingevoerd voor de behandeling van auto-immuunziektes. Dat biedt hoop voor miljoenen mensen over de hele wereld die aan deze ziektes lijden. De nieuwe behandeling is belangrijk, omdat het lichaam door auto-immuunziektes zichzelf bestrijdt. Dit is het gevolg van een falend onderscheid tussen lichaamseigen weefsel en cellen enerzijds en cellen van buitenaf anderzijds.

Hoogleraar Kishimoto zei dit in een door de King Faisal International Prize georganiseerde lezing aan de Faculteit voor Geneeskunde van de King Saud Universiteit in Riyad. Hij won de prestigieuze prijs onlangs voor de ontdekking van het chemische reactiepad van endogene interleukine-6 en de rol daarvan in ontstekingsziekten en auto-immuunziekten.

Adoption of New Therapy for Autoimmune Diseases to Benefit Millions of Patients in Over 100 Countries

Recipient of King Faisal International Prize for Medicine 2017 highlights key research findings during lecture event

RIYADH, Saudi Arabia‚Äď(BUSINESS WIRE)‚Äď Professor¬†Tadamitsu Kishimoto¬†of the Osaka University, winner of the¬†King Faisal International Prize¬†for Medicine 2017, has stated that more than 100 countries, including Saudi Arabia, have adopted an effective biological approach in the treatment of autoimmune diseases, raising hopes for millions of people around the world who suffer from such diseases. The new treatment is significant considering that autoimmune diseases, which result from the failure of immune system cells to differentiate between the body‚Äôs tissues and cells, and alien tissues and cells, cause the body to fight against itself.

Professor Tadamitsu Kishimoto (Photo: ME NewsWire)

Professor Kishimoto, who was recently awarded the prestigious prize for the discovery of endogenous chemical interleukin-6’s (IL-6) pathway and its role in inflammatory and autoimmune diseases, said this while delivering a lecture organised by the King Faisal International Prize at the College of Medicine at the King Saud University in Riyadh. This lecture reflected the King Faisal International Prize’s efforts to promote the dissemination, transfer and localisation of knowledge by honouring humanitarian achievements and celebrating everything that serves people and improves their wellbeing.

A world-renowned immunologist, Professor Kishimoto has, through his research during the last 30 years, developed an IL-6 receptor-blocking antibody that has been recognized as the first approved treatment for diseases such progressive sclerosis and rheumatoid arthritis.

‚ÄúThe discovery of IL-6 receptor-blocking antibody has led to a major breakthrough in the treatment of autoimmune diseases. It has been approved for treatment in over 100 countries, including Saudi Arabia, Japan, the EU, and the US. Today almost one million people suffering from such diseases are being successfully treated with this antibody,‚ÄĚ stated Kishimoto.

Besides being an immune protein, IL-6 is responsible for fever in autoimmune, infectious or non-infectious diseases, and is produced in the body wherever there is inflammation. IL-6 is implicated in a wide variety of inflammation-associated diseases, including diabetes mellitus and systemic juvenile rheumatoid arthritis.

The discovery of the antibody has not only led to the treatment of inflammatory diseases but has also paved the way for the training of several immunologists in all parts of the world, added Professor Kishimoto.

The King Faisal International Prize in Medicine has earlier been awarded to two researchers from Japan. Tetsuro Fujiwara was the first recipient when he shared the award with Bengt A. Robertson of Sweden in 1996 for research on the management of Neonatal Respiratory Distress Syndrome. Shinya Yamanaka was the second winner, sharing the prize in 2011 with James Alexander Thomson of USA. Yamanaka later won the Nobel Prize in 2012.

To know more about King Faisal International Prize, visit our website:

www.kfip.org

*Source: ME NewsWire

View source version on businesswire.com: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=51578826&lang=en

Contacts

for King Faisal Foundation

Hussain Abu Hajer, +966568685008

Hussain@hadathgroup.com

or

Rima Abuobaid

UAE Mob: +971509155921

KSA Mob: +966556890730

rima@hadathgroup.com

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is.